Literature DB >> 25783798

Characterization of multiple sclerosis plaques using susceptibility-weighted imaging at 1.5 T: can perivenular localization improve specificity of imaging criteria?

John I Lane1, Bradley Bolster, Norbert G Campeau, Kirk M Welker, Julie R Gilbertson.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to determine if magnetic resonance (MR) susceptibility-weighted imaging (SWI) can increase the conspicuity of corticomedullary veins within the white matter lesions of multiple sclerosis (MS) and, thus, aid in distinguishing plaques from leukoaraiosis.
METHODS: We retrospectively reviewed MR examinations in 21 patients with a clinical diagnosis of MS and 18 patients with a clinical diagnosis of dementia. Examinations included fluid-attenuated inversion recovery (FLAIR) and SWI sequences obtained in the axial plane. Lesions greater than 5 mm in diameter on the axial FLAIR sequence were identified as periventricular or subcortical. Three neuroradiologists evaluated SWI images, compared with FLAIR, for a centrally located signal void in each lesion that was scored as present, absent, or indeterminate.
RESULTS: In patients with MS, central veins were present in both periventricular lesions (75%, P < 0.001) and subcortical lesions (52%, P < 0.005). In patients with dementia, central veins were seen much less frequently in subcortical lesions (14%, P < 0.001); their association with periventricular lesions was not significant.
CONCLUSIONS: Central veins were detected in MS lesions with a significantly greater frequency than that in patients with dementia. Susceptibility-weighted imaging increases the conspicuity of corticomedullary veins and may improve the specificity of MR findings in MS.

Entities:  

Mesh:

Year:  2015        PMID: 25783798     DOI: 10.1097/RCT.0000000000000233

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  6 in total

1.  Multiple sclerosis: High prevalence of the 'central vein' sign in white matter lesions on susceptibility-weighted images.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Angelo Gambino; Martina Sciortino; Massimo Midiri
Journal:  Neuroradiol J       Date:  2018-03-22

Review 2.  Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

Authors:  Ruth Geraldes; Margaret M Esiri; Gabriele C DeLuca; Jacqueline Palace
Journal:  Brain Pathol       Date:  2017-03-12       Impact factor: 6.508

Review 3.  The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Authors:  Pascal Sati; Jiwon Oh; R Todd Constable; Nikos Evangelou; Charles R G Guttmann; Roland G Henry; Eric C Klawiter; Caterina Mainero; Luca Massacesi; Henry McFarland; Flavia Nelson; Daniel Ontaneda; Alexander Rauscher; William D Rooney; Amal P R Samaraweera; Russell T Shinohara; Raymond A Sobel; Andrew J Solomon; Constantina A Treaba; Jens Wuerfel; Robert Zivadinov; Nancy L Sicotte; Daniel Pelletier; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-11-11       Impact factor: 42.937

4.  Multiple sclerosis: prevalence of the 'central vein' sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Alberto Iaia; Aurelia Banco; Massimo Galia; Massimo Midiri
Journal:  Neuroradiol J       Date:  2021-04-19

5.  FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?

Authors:  T Campion; R J P Smith; D R Altmann; G C Brito; B P Turner; J Evanson; I C George; P Sati; D S Reich; M E Miquel; K Schmierer
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

6.  The "Central Vein Sign" on T2*-weighted Images as a Diagnostic Tool in Multiple Sclerosis: A Systematic Review and Meta-analysis using Individual Patient Data.

Authors:  Chong Hyun Suh; Sang Joon Kim; Seung Chai Jung; Choong Gon Choi; Ho Sung Kim
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.